Physician profile
Mark Eid
NPI 1861695181
$1,021.20
in general payments reported to CMS, 2019-2025
13 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.11 · 2020: $45.74 · 2021: $149 · 2022: $18.44 · 2023: $246 · 2024: $232 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.24 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $272.22 | 2023-2025 | Eluvia, Ranger |
| Leo Pharma INC. | $128.45 | 2023-2025 | Adbry |
| Genzyme Corporation | $125.38 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $110.47 | 2024-2025 | Zoryve |
| Abbvie INC. | $64.70 | 2020-2021 | |
| Janssen Biotech, INC. | $58.84 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $52.43 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $52.05 | 2019-2022 | |
| Organogenesis INC. | $42.60 | 2024 | |
| Genentech USA, INC. | $37.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.12 | 2023 | Sotyktu |
| Ucb, INC. | $28.67 | 2020 | |
| Pfizer INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.